Last updated: 07/21/2020 16:30:06
A Phase 1 relative bioavailability study of ambrisentan and tadalfil fixed dose combination tablets in healthy subjects
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase 1 study to demonstrate the relative bioavailability of fixed dose combinations of ambrisentan and tadalafil in healthy subjects
Trial description: This study is designed to understand the relative bioavailability (proportion of the administered dose that is absorbed into the bloodstream) of several fixed dose combinations (FDCs) tablets of ambrisentan and tadalafil for further development and to provide pharmacokinetic (PK – what the body does to the drug) data to enable a pivotal bioequivalence (BE - the relationship between two preparations of the same drug in the same dosage form that have a similar bioavailability) study. Depending on formulation work, the study will allow up to 8 new FDCs to be compared with the reference of ambrisentan and tadalafil monotherapies. The study will also evaluate up to 2 of the new formulations, that may be taken in to a BE study, to be tested for any effect on pharmacokinetics of the FDC in both fed and fasted state. This is a single centre, Phase 1, single dose, randomised, open label crossover study with 3 study parts; each study part will have up to a 5 way crossover in healthy subjects. Part 1 of the study will evaluate four formulations of the FDC (ambrisentan 10 milligram [mg] + tadalafil 40 mg) and the reference of the 2 monotherapy components taken concurrently (ambrisentan 10 mg and tadalafil 40 mg) in the fasted stated. If successful formulations are identified in this part of the study, then they will be re-formulated and tested in part 2. If no successful formulations are identified in part 1 of the study, then part 2 will be utilized to look at up to 4 new FDC formulations. However, if only two formulations, or less, are evaluated in part 2 then the FDC formulations may be tested both fed and fasted to assess food effect and part 3 will not be required. If successful formulations are identified in this study part, then up to 2 of these may be tested, for food effect, in Part 3 if not already assessed in this part. Therefore, part 3 is optional and utility is dependent on the results of the previous study parts.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Maximum observed concentration (Cmax) of ambrisentan and tadalafil in FDC (ambrisentan 10 mg + tadalafil 40 mg) and montherapies (ambrisentan 10 mg & tadalafil 40 mg) - Part 1
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Area under the plasma concentration time curve (AUC) from time zero to infinite (inf) time, AUC (0-inf) of ambrisentan and tadalafil in FDC (ambrisentan 10 mg + tadalafil 40 mg) and montherapies (ambrisentan 10 mg & tadalafil 40 mg) - Part 1
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC from time of dose to last measurable concentration (AUC [0-t]), in FDC, (ambrisentan 10 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 10 mg & tadalafil 40 mg), under fasting- Part 1
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Cmax of ambrisentan and tadalafil in FDC (ambrisentan 10 mg + tadalafil 40 mg) and montherapies (ambrisentan 10 mg & tadalafil 40 mg) - Part 2
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0 - inf) for FDC, (ambrisentan 10 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 10 mg & tadalafil 40 mg), under fasting- Part 2
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0-t) for FDC, (ambrisentan 10 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 10 mg & tadalafil 40 mg), under fasting- Part 2
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Cmax for ambrisentan and tadalafil, following candidate FDC (ambrisentan 10 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 10 mg & tadalafil 40 mg), under fed and fasted conditions-Part 3A
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0-inf) for ambrisentan and tadalafil, following candidate FDC (ambrisentan 10 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 10 mg & tadalafil 40 mg), under fed and fasted conditions-3A
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0-t) for ambrisentan and tadalafil, following candidate FDC (ambrisentan 10 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 10 mg & tadalafil 40 mg), under fed and fasted conditions-Part 3A
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Cmax for ambrisentan and tadalafil, FDCs (ambrisentan 5 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 5 mg & tadalafil 40 mg) under fasted conditions-3B
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0-inf) for ambrisentan and tadalafil, FDCs (ambrisentan 5 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 5 mg & tadalafil 40 mg) under fasted conditions-3B
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0-t) for ambrisentan and tadalafil, FDCs (ambrisentan 5 mg + tadalafil 40 mg) relative to reference monotherapies tested (ambrisentan 5 mg & tadalafil 40 mg) under fasted conditions-3B
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Cmax for ambrisentan and tadalafil, FDCs (ambrisentan 5 mg + tadalafil 20 mg) relative to reference monotherapies tested (ambrisentan 5 mg & tadalafil 20 mg) under fasted conditions-3B
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0-inf) for ambrisentan and tadalafil, FDCs (ambrisentan 5 mg + tadalafil 20 mg) relative to reference monotherapies tested (ambrisentan 5 mg & tadalafil 20 mg) under fasted conditions-3B
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
AUC (0-t) for ambrisentan and tadalafil, FDCs (ambrisentan 5 mg + tadalafil 20 mg) relative to reference monotherapies tested (ambrisentan 5 mg & tadalafil 20 mg) under fasted conditions- Part 3B
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Secondary outcomes:
Time taken to reach maximum concentration (tmax) for ambrisentan and tadalafil in FDC and reference treatment - Part 1
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Time taken to reach maximum concentration (tmax) for ambrisentan and tadalafil in FDC and reference treatment - Part 2
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Time taken to reach maximum concentration (tmax) for ambrisentan and tadalafil in FDC and reference treatment - Part 3A
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Time taken to reach maximum concentration (tmax) for ambrisentan and tadalafil in FDC and reference treatment - Part 3B
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Plasma half life (t1/2) for ambrisentan and tadalafil in FDC and reference treatment under fed and fasted condition- Part1
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Plasma t1/2 for ambrisentan and tadalafil in FDC and reference treatment under fed and fasted condition- Part 2
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Plasma t1/2 for ambrisentan and tadalafil in FDC and reference treatment under fed and fasted condition- Part 3A
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose
Plasma t1/2 for ambrisentan and tadalafil in FDC and reference treatment under fed and fasted condition- Part 3B
Timeframe: Pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48, and 72 hours postdose
Change from Baseline in Vital- Systolic blood pressure (SBP) and diastolic blood pressure (DBP), Part 1
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Heart rate, Part 1
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital- Temperature, Part 1
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Respiratory rate, Part 1
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital- SBP and DBP, Part 2
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Heart rate, Part 2
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital- Temperature, Part 2
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Respiratory rate, Part 2
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital- SBP and DBP, Part 3A
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Heart rate, Part 3A
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital- Temperature, Part 3A
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Respiratory rate, Part 3A
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital- SBP and DBP, Part 3B
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Heart rate, Part 3B
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital- Temperature, Part 3B
Timeframe: Baseline and Up to Day 3
Change from Baseline in Vital signs-Respiratory rate, Part 3-B
Timeframe: Baseline and Up to Day 3
Number of participants with abnormal electrocardiogram (ECG) findings, -Part 1
Timeframe: Up to Day 3
Number of participants with abnormal ECG findings, -Part 2
Timeframe: Up to Day 3
Number of participants with abnormal ECG findings, -Part 3A
Timeframe: Up to Day 3
Number of participants with abnormal ECG findings, -Part 3B
Timeframe: Up to Day 3
Number of participants with hematology values of Potential Clinical Importance (PCI)- Part1
Timeframe: Up to Day 3
Number of participants with hematology values of PCI - Part 2
Timeframe: Day 2
Number of participants with hematology values of PCI - Part 3A
Timeframe: Day 2
Number of participants with hematology values of PCI - Part 3B
Timeframe: Day 2
Number of participants with Clinical chemistry values of PCI- Part1
Timeframe: Day 2
Number of participants with Clinical chemistry values of PCI- Part 2
Timeframe: Day 2
Number of participants with Clinical chemistry values of PCI- Part 3A
Timeframe: Day 2
Number of participants with Clinical chemistry values of PCI- Part 3B
Timeframe: Day 2
Number of participants with abnormal Urinalysis results by dipstick method-Part 1
Timeframe: Up to Day 2
Number of participants with Urinalysis results by dipstick analysis-Part 2
Timeframe: Up to Day 2
Number of participants with Urinalysis results by dipstick analysis-Part 3A
Timeframe: Up to Day 2
Number of participants with Urinalysis results by dipstick analysis-Part 3B
Timeframe: Up to Day 2
Number of participants with Serious adverse events (SAEs) and Adverse events (AEs)-Part 1
Timeframe: Up to 42 days
Number of participants with SAEs and AEs-Part 2
Timeframe: Up to 35 days
Number of participants with SAEs and AEs-Part 3A
Timeframe: Up to 44 days
Number of participants with SAEs and AEs-Part 3B
Timeframe: Up to 44 days
Interventions:
Enrollment:
112
Primary completion date:
2017-04-08
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Malek Okour, Adeep Puri, Geng Chen, Kathleen Port, Alessandro Berni, Sanjeev Khindri, Ian Schneider, David Tenero. A Phase 1 study to demonstrate the relative bioavailability and bioequivalence of fixed dose combinations of ambrisentan and tadalafil in healthy subjects. Clin Ther. 2019;41(6):Pages 1110-1127
DOI: 10.1016/j.clinthera.2019.04.007
PMID: 31060740
Medical condition
Hypertension, Pulmonary
Product
ambrisentan, ambrisentan/tadalafil, tadalafil
Collaborators
Covance Harrogate, Hammersmith Medicines Research Ltd
Study date(s)
March 2016 to August 2017
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 60 years
Accepts healthy volunteers
Yes
- Between 18 and 60 years of age inclusive, at the time of signing the informed consent.
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, vital signs and cardiac monitoring (ECG and 24 hour Holter). A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator, in consultation with Medical Monitor if required, judges and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- A blood pressure <100/55 millimetre of Mercury (mm Hg).
- Haemoglobin (Hb) below normal range: Hb <133 (gram per litre) g/L for males and Hb <114 g/L for females
Inclusion and exclusion criteria
Inclusion criteria:
- Between 18 and 60 years of age inclusive, at the time of signing the informed consent.
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, vital signs and cardiac monitoring (ECG and 24 hour Holter). A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator, in consultation with Medical Monitor if required, judges and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Body weight >= 50 Kilogram (kg) (110 pounds [lbs]) for men and >= 45 kg (99lbs) for women and body mass index (BMI) within the range 18 – 30 kg per square metre (m^2) (inclusive)
- Male or Female. Female with non-reproductive potential defined as, Pre-menopausal females with one of the following: Documented tubal ligation or Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion or Hysterectomy or Documented Bilateral Oophorectomy, Documented Postmenopausal defined as 12 months of spontaneous amenorrhea
- Capable of giving signed informed consent.
Exclusion criteria:
- A blood pressure <100/55 millimetre of Mercury (mm Hg).
- Haemoglobin (Hb) below normal range: Hb <133 (gram per litre) g/L for males and Hb <114 g/L for females
- Alanine amino transferase (ALT) and bilirubin >1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35 percentage [%]).
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- Corrected QT (QTc) >450 milliseconds (msec). The QTc is the QT interval corrected for heart rate according to Bazett’s formula (QTcB), Fridericia’s formula (QTcF), and/or another method, machine-read or manually over-read.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 gram (g) of alcohol: a half-pint (~240 millilitre [mL]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- Smoking more than 5 cigarettes per week and subjects must be able to abstain from smoking for a 24 hour period prior to dose and any time whilst in the clinical unit.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at Screening or within 3 months prior to first dose of study treatment.
- A positive test for human immuno-deficiency virus (HIV) antibody
- A positive pre-study drug/alcohol screen.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within previous 3 months
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Trial location(s)
Study documents
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2017-04-08
Actual study completion date
2017-04-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website